Panel: From Reactive to Predictive: Manufacturing Intelligence in Biologics Production
Day 2 Next-Gen Bio Stage
07/10/2026 16:15 - 17:00pm
Contributors
Thomas Halfmann : Head of Pharma Strategy - eschbach gmbh
Matthias Müllner : CEO - bespark*bio
Krisha Patel : Co-Founder - Assurea
Francesco Destro : Head of Engineering - BioCurie Inc.
Rene Fischer : Digital Strategy Delivery Specialist - Roche
The development of manufacturing processes for novel biotherapeutics remains a key bottleneck in bringing advanced therapies to patients. Early-stage process development is often dominated by trial-and-error experimentation, leading to inefficiencies and increased risk. However, biologics manufacturing is now moving beyond deviation management and post-event troubleshooting toward predictive, intelligence-driven operations.
Advances in real-time monitoring, advanced analytics, and AI-enabled process control are enabling earlier risk detection, tighter process consistency, and improved yield performance. By combining structured development approaches with data-driven tools—including targeted experiments, process modelling, and digital twins—the industry can shift bioprocessing toward a more predictive paradigm that reduces experimental workload while improving process understanding, robustness, and scalability.
Yet adoption remains uneven. While leading manufacturers are embedding predictive capabilities across development and commercial production, others face barriers around validation standards, data integration, legacy infrastructure, and workforce readiness. The result is a widening operational divide between early adopters and traditional operators.This panel will examine whether predictive manufacturing is becoming a competitive necessity rather than a digital aspiration, and what it truly takes to implement it at scale.